One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Revisiting FDA Approval of Aducanumab
G. Caleb Alexander, M.D., David S. Knopman, M.D., Scott S. Emerson, M.D., Ph.D., Bruce Ovbiagele, M.D., Richard J. Kryscio, Ph.D., Joel S. Perlmutter, M.D., and Aaron S. Kesselheim, M.D., J.D.
doi : 10.1056/nejmp2110468
N Engl J Med 2021; 385:769-771
Controversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab
Gil D. Rabinovici, M.D.
doi : 10.1056/nejmp2111320
N Engl J Med 2021; 385:771-774
A Pink Salwar
Padmasayee Papineni, F.R.C.P., D.T.M.&H.
doi : 10.1056/nejmp2104037
N Engl J Med 2021; 385:774-775
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
The REMAP-CAP, ACTIV-4a, and ATTACC Investigators
doi : 10.1056/nejmoa2103417
N Engl J Med 2021; 385:777-789
Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
The ATTACC, ACTIV-4a, and REMAP-CAP Investigators
doi : 10.1056/nejmoa2105911
N Engl J Med 2021; 385:790-802
Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.
A Monoclonal Antibody for Malaria Prevention
Martin R. Gaudinski, M.D., Nina M. Berkowitz, M.P.H., Azza H. Idris, M.D., Ph.D., Emily E. Coates, Ph.D., LaSonji A. Holman, F.N.P., Floreliz Mendoza, R.N., Ingelise J. Gordon, R.N., Sarah H. Plummer, M.S.N., C.R.N.P., Olga Trofymenko, M.D., Zonghui Hu, Ph.D., Andrezza Campos Chagas, Ph.D., Sarah O’Connell, M.S., Manjula Basappa, B.S., Naomi Douek, Sandeep R. Narpala, M.S., Christopher R. Barry, M.S., Alicia T. Widge, M.D., M.S., Renunda Hicks, Seemal F. Awan, M.D., Richard L. Wu, M.D., Somia Hickman, Ph.D., Diane Wycuff, Ph.D., Judy A. Stein, M.B.A., Christopher Case, Ph.D., Brian P. Evans, Ph.D., Kevin Carlton, M.S., Jason G. Gall, Ph.D., Sandra Vazquez, M.S., Britta Flach, Ph.D., Grace L. Chen, M.D., Joseph R. Francica, Ph.D., Barbara J. Flynn, M.S., Neville K. Kisalu, Ph.D., Edmund V. Capparelli, Pharm.D., Adrian McDermott, Ph.D., John R. Mascola, M.D., Julie E. Ledgerwood, D.O., and Robert A. Seder, M.D. for the VRC 612 Study Team*
doi : 10.1056/nejmoa2034031
N Engl J Med 2021; 385:803-814
Additional interventions are needed to reduce the morbidity and mortality caused by malaria.
Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes
Peter J. Barry, M.D., Marcus A. Mall, M.D., Antonio ?lvarez, M.D., Carla Colombo, M.D., Karin M. de Winter-de Groot, M.D., Isabelle Fajac, M.D., Ph.D., Kimberly A. McBennett, M.D., Ph.D., Edward F. McKone, M.D., Bonnie W. Ramsey, M.D., Sivagurunathan Sutharsan, M.D., Jennifer L. Taylor-Cousar, M.D., M.S.C.S., Elizabeth Tullis, M.D., Neil Ahluwalia, M.D., Lucy S. Jun, Ph.D., Samuel M. Moskowitz, M.D., Valentin Prieto-Centurion, M.D., Simon Tian, M.D., David Waltz, M.D., Fengjuan Xuan, Ph.D., Yaohua Zhang, Ph.D., Steven M. Rowe, M.D., M.S.P.H., and Deepika Polineni, M.D., M.P.H. for the VX18-445-104 Study Group*
doi : 10.1056/nejmoa2100665
N Engl J Med 2021; 385:815-825
Elexacaftor–tezacaftor–ivacaftor is a small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen shown to be efficacious in patients with at least one Phe508del allele, which indicates that this combination can modulate a single Phe508del allele. In patients whose other CFTR allele contains a gating or residual function mutation that is already effectively treated with previous CFTR modulators (ivacaftor or tezacaftor–ivacaftor), the potential for additional benefit from restoring Phe508del CFTR protein function is unclear.
Heparin Resistance — Clinical Perspectives and Management Strategies
Jerrold H. Levy, M.D., and Jean M. Connors, M.D.
doi : 10.1056/nejmra2104091
N Engl J Med 2021; 385:826-832
Hypervirulent Klebsiella pneumoniae
Qiong Zou, M.D., and Yang Li, M.D.
doi : 10.1056/nejmicm2101602
N Engl J Med 2021; 385:833
Circinate Syphilitic Lesions
Suruthi Purushothaman, M.D., and Bhargavi Mayakuntla, M.D.
doi : 10.1056/nejmicm2035514
N Engl J Med 2021; 385:e26
Case 26-2021: A 49-Year-Old Man with Relapsed Acute Myeloid Leukemia
Andrew M. Brunner, M.D., Richard A. Newcomb, M.D., Yi-Bin Chen, M.D., and Andrew M. Crabbe, M.D., Ph.D.
doi : 10.1056/nejmcpc2103458
N Engl J Med 2021; 385:834-843
Surviving Covid-19 with Heparin?
Hugo ten Cate, M.D., Ph.D.
doi : 10.1056/nejme2111151
N Engl J Med 2021; 385:845-846
Audio Interview: Assessing Vaccine Safety
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/nejme2114106
N Engl J Med 2021; 385:e37
Modeling Human Cardiac Chambers with Organoids
Deepak Srivastava, M.D.
doi : 10.1056/nejmcibr2108627
N Engl J Med 2021; 385:847-849
Remembering Past Lessons about Structural Racism — Recentering Black Theorists of Health and Society
Alexandre White, Ph.D., Rachel L.J. Thornton, M.D., Ph.D., and Jeremy A. Greene, M.D., Ph.D.
doi : 10.1056/nejmms2035550
N Engl J Med 2021; 385:850-855
An Appropriate Use of Accelerated Approval — Aducanumab for Alzheimer’s Disease
doi : 10.1056/nejmc2111960
N Engl J Med 2021; 385:856-857
Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia
doi : 10.1056/nejmc2109465
N Engl J Med 2021; 385:857-859
Tympanostomy Tubes or Medical Management for Recurrent Acute Otitis Media
doi : 10.1056/nejmc2109725
N Engl J Med 2021; 385:860-862
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
doi : 10.1056/nejmx210012
N Engl J Med 2021; 385:864
